ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Urate-stimulating Excretion Agents Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-9G18172
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Urate stimulating Excretion Agents Market Research Report 2024
BUY CHAPTERS

Global Urate-stimulating Excretion Agents Market Research Report 2026

Code: QYRE-Auto-9G18172
Report
2026-02-11
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Fuji yakuhin
Lannett Company
TEVA
Eisai Co Ltd
Astrazeneca plc
Towa Pharmaceutical
Excella Gmbh

Urate-stimulating Excretion Agents Market

The global Urate-stimulating Excretion Agents market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Urate-stimulating Excretion Agents competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Urate-stimulating excretion agents are a class of medications designed to lower blood uric acid levels by enhancing its elimination from the body.They work by inhibiting the reabsorption of uric acid in the kidneys,which increases its excretion in the urine.These agents are used primarily in the treatment of chronic gout and hyperuricemia.
The North American market for Urate-stimulating Excretion Agents is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Urate-stimulating Excretion Agents is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Urate-stimulating Excretion Agents include Fuji Yakuhin, Lannett Company, Teva, Eisai, AstraZeneca, Towa Pharmaceutical, Excella, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Urate-stimulating Excretion Agents market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Urate-stimulating Excretion Agents. The Urate-stimulating Excretion Agents market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Urate-stimulating Excretion Agents market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Urate-stimulating Excretion Agents manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Urate-stimulating Excretion Agents Market Report

Report Metric Details
Report Name Urate-stimulating Excretion Agents Market
Segment by Type
  • Benzbromarone
  • Lesinurad
  • Dotinurad
  • Probenecid
  • Other
by Application
  • Hospitals and Clinics
  • Retail Pharmacies
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Fuji Yakuhin, Lannett Company, Teva, Eisai, AstraZeneca, Towa Pharmaceutical, Excella
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Urate-stimulating Excretion Agents manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Urate-stimulating Excretion Agents sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Urate-stimulating Excretion Agents Market report?

Ans: The main players in the Urate-stimulating Excretion Agents Market are Fuji Yakuhin, Lannett Company, Teva, Eisai, AstraZeneca, Towa Pharmaceutical, Excella

What are the Application segmentation covered in the Urate-stimulating Excretion Agents Market report?

Ans: The Applications covered in the Urate-stimulating Excretion Agents Market report are Hospitals and Clinics, Retail Pharmacies, Other

What are the Type segmentation covered in the Urate-stimulating Excretion Agents Market report?

Ans: The Types covered in the Urate-stimulating Excretion Agents Market report are Benzbromarone, Lesinurad, Dotinurad, Probenecid, Other

1 Urate-stimulating Excretion Agents Market Overview
1.1 Product Definition
1.2 Urate-stimulating Excretion Agents by Type
1.2.1 Global Urate-stimulating Excretion Agents Market Value by Type: 2025 vs 2032
1.2.2 Benzbromarone
1.2.3 Lesinurad
1.2.4 Dotinurad
1.2.5 Probenecid
1.2.6 Other
1.3 Urate-stimulating Excretion Agents by Application
1.3.1 Global Urate-stimulating Excretion Agents Market Value by Application: 2025 vs 2032
1.3.2 Hospitals and Clinics
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Urate-stimulating Excretion Agents Market Size Estimates and Forecasts
1.4.1 Global Urate-stimulating Excretion Agents Revenue 2021–2032
1.4.2 Global Urate-stimulating Excretion Agents Sales 2021–2032
1.4.3 Global Urate-stimulating Excretion Agents Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Urate-stimulating Excretion Agents Market Competition by Manufacturers
2.1 Global Urate-stimulating Excretion Agents Sales Market Share by Manufacturers (2021–2026)
2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Urate-stimulating Excretion Agents Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Urate-stimulating Excretion Agents, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Urate-stimulating Excretion Agents, Product Types and Applications
2.7 Global Key Manufacturers of Urate-stimulating Excretion Agents, Date of Entry into the Industry
2.8 Global Urate-stimulating Excretion Agents Market Competitive Situation and Trends
2.8.1 Global Urate-stimulating Excretion Agents Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Urate-stimulating Excretion Agents Players Market Share by Revenue
2.8.3 Global Urate-stimulating Excretion Agents Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Urate-stimulating Excretion Agents Market Scenario by Region
3.1 Global Urate-stimulating Excretion Agents Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Urate-stimulating Excretion Agents Sales by Region: 2021–2032
3.2.1 Global Urate-stimulating Excretion Agents Sales by Region: 2021–2026
3.2.2 Global Urate-stimulating Excretion Agents Sales by Region: 2027–2032
3.3 Global Urate-stimulating Excretion Agents Revenue by Region: 2021–2032
3.3.1 Global Urate-stimulating Excretion Agents Revenue by Region: 2021–2026
3.3.2 Global Urate-stimulating Excretion Agents Revenue by Region: 2027–2032
3.4 North America Urate-stimulating Excretion Agents Market Facts & Figures by Country
3.4.1 North America Urate-stimulating Excretion Agents Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Urate-stimulating Excretion Agents Sales by Country (2021–2032)
3.4.3 North America Urate-stimulating Excretion Agents Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Urate-stimulating Excretion Agents Market Facts & Figures by Country
3.5.1 Europe Urate-stimulating Excretion Agents Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Urate-stimulating Excretion Agents Sales by Country (2021–2032)
3.5.3 Europe Urate-stimulating Excretion Agents Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Urate-stimulating Excretion Agents Market Facts & Figures by Region
3.6.1 Asia Pacific Urate-stimulating Excretion Agents Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Urate-stimulating Excretion Agents Sales by Region (2021–2032)
3.6.3 Asia Pacific Urate-stimulating Excretion Agents Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Urate-stimulating Excretion Agents Market Facts & Figures by Country
3.7.1 Latin America Urate-stimulating Excretion Agents Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Urate-stimulating Excretion Agents Sales by Country (2021–2032)
3.7.3 Latin America Urate-stimulating Excretion Agents Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Urate-stimulating Excretion Agents Market Facts & Figures by Country
3.8.1 Middle East and Africa Urate-stimulating Excretion Agents Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (2021–2032)
3.8.3 Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Urate-stimulating Excretion Agents Sales by Type (2021–2032)
4.1.1 Global Urate-stimulating Excretion Agents Sales by Type (2021–2026)
4.1.2 Global Urate-stimulating Excretion Agents Sales by Type (2027–2032)
4.1.3 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021–2032)
4.2 Global Urate-stimulating Excretion Agents Revenue by Type (2021–2032)
4.2.1 Global Urate-stimulating Excretion Agents Revenue by Type (2021–2026)
4.2.2 Global Urate-stimulating Excretion Agents Revenue by Type (2027–2032)
4.2.3 Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021–2032)
4.3 Global Urate-stimulating Excretion Agents Price by Type (2021–2032)
5 Segment by Application
5.1 Global Urate-stimulating Excretion Agents Sales by Application (2021–2032)
5.1.1 Global Urate-stimulating Excretion Agents Sales by Application (2021–2026)
5.1.2 Global Urate-stimulating Excretion Agents Sales by Application (2027–2032)
5.1.3 Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021–2032)
5.2 Global Urate-stimulating Excretion Agents Revenue by Application (2021–2032)
5.2.1 Global Urate-stimulating Excretion Agents Revenue by Application (2021–2026)
5.2.2 Global Urate-stimulating Excretion Agents Revenue by Application (2027–2032)
5.2.3 Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021–2032)
5.3 Global Urate-stimulating Excretion Agents Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Fuji Yakuhin
6.1.1 Fuji Yakuhin Company Information
6.1.2 Fuji Yakuhin Description and Business Overview
6.1.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolio
6.1.5 Fuji Yakuhin Recent Developments/Updates
6.2 Lannett Company
6.2.1 Lannett Company Company Information
6.2.2 Lannett Company Description and Business Overview
6.2.3 Lannett Company Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Lannett Company Urate-stimulating Excretion Agents Product Portfolio
6.2.5 Lannett Company Recent Developments/Updates
6.3 Teva
6.3.1 Teva Company Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Teva Urate-stimulating Excretion Agents Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Eisai
6.4.1 Eisai Company Information
6.4.2 Eisai Description and Business Overview
6.4.3 Eisai Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Eisai Urate-stimulating Excretion Agents Product Portfolio
6.4.5 Eisai Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 AstraZeneca Urate-stimulating Excretion Agents Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Towa Pharmaceutical
6.6.1 Towa Pharmaceutical Company Information
6.6.2 Towa Pharmaceutical Description and Business Overview
6.6.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolio
6.6.5 Towa Pharmaceutical Recent Developments/Updates
6.7 Excella
6.7.1 Excella Company Information
6.7.2 Excella Description and Business Overview
6.7.3 Excella Urate-stimulating Excretion Agents Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Excella Urate-stimulating Excretion Agents Product Portfolio
6.7.5 Excella Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Urate-stimulating Excretion Agents Industry Chain Analysis
7.2 Urate-stimulating Excretion Agents Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Urate-stimulating Excretion Agents Production Mode & Process Analysis
7.4 Urate-stimulating Excretion Agents Sales and Marketing
7.4.1 Urate-stimulating Excretion Agents Sales Channels
7.4.2 Urate-stimulating Excretion Agents Distributors
7.5 Urate-stimulating Excretion Agents Customer Analysis
8 Urate-stimulating Excretion Agents Market Dynamics
8.1 Urate-stimulating Excretion Agents Industry Trends
8.2 Urate-stimulating Excretion Agents Market Drivers
8.3 Urate-stimulating Excretion Agents Market Challenges
8.4 Urate-stimulating Excretion Agents Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Fuji yakuhin
Lannett Company
TEVA
Eisai Co Ltd
Astrazeneca plc
Towa Pharmaceutical
Excella Gmbh
List of Tables
 Table 1. Global Urate-stimulating Excretion Agents Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Urate-stimulating Excretion Agents Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Urate-stimulating Excretion Agents Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Urate-stimulating Excretion Agents Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Urate-stimulating Excretion Agents Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Urate-stimulating Excretion Agents Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Urate-stimulating Excretion Agents Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Urate-stimulating Excretion Agents Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Urate-stimulating Excretion Agents, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Urate-stimulating Excretion Agents, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Urate-stimulating Excretion Agents, Product Types and Applications
 Table 12. Global Key Manufacturers of Urate-stimulating Excretion Agents, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Urate-stimulating Excretion Agents Companies by Tier (Tier 1, Tier 2, Tier 3), based on Urate-stimulating Excretion Agents Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Urate-stimulating Excretion Agents Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Urate-stimulating Excretion Agents Sales by Region (K Units), 2021–2026
 Table 18. Global Urate-stimulating Excretion Agents Sales Market Share by Region (2021–2026)
 Table 19. Global Urate-stimulating Excretion Agents Sales by Region (K Units), 2027–2032
 Table 20. Global Urate-stimulating Excretion Agents Sales Market Share by Region (2027–2032)
 Table 21. Global Urate-stimulating Excretion Agents Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2021–2026)
 Table 23. Global Urate-stimulating Excretion Agents Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Urate-stimulating Excretion Agents Revenue Market Share by Region (2027–2032)
 Table 25. North America Urate-stimulating Excretion Agents Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Urate-stimulating Excretion Agents Sales by Country (K Units), 2021–2026
 Table 27. North America Urate-stimulating Excretion Agents Sales by Country (K Units), 2027–2032
 Table 28. North America Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Urate-stimulating Excretion Agents Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Urate-stimulating Excretion Agents Sales by Country (K Units), 2021–2026
 Table 32. Europe Urate-stimulating Excretion Agents Sales by Country (K Units), 2027–2032
 Table 33. Europe Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Urate-stimulating Excretion Agents Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Urate-stimulating Excretion Agents Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Urate-stimulating Excretion Agents Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Urate-stimulating Excretion Agents Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Urate-stimulating Excretion Agents Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Urate-stimulating Excretion Agents Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Urate-stimulating Excretion Agents Sales by Country (K Units), 2021–2026
 Table 42. Latin America Urate-stimulating Excretion Agents Sales by Country (K Units), 2027–2032
 Table 43. Latin America Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Urate-stimulating Excretion Agents Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Urate-stimulating Excretion Agents Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Urate-stimulating Excretion Agents Sales (K Units) by Type (2021–2026)
 Table 51. Global Urate-stimulating Excretion Agents Sales (K Units) by Type (2027–2032)
 Table 52. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021–2026)
 Table 53. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2027–2032)
 Table 54. Global Urate-stimulating Excretion Agents Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Urate-stimulating Excretion Agents Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021–2026)
 Table 57. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2027–2032)
 Table 58. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Urate-stimulating Excretion Agents Sales (K Units) by Application (2021–2026)
 Table 61. Global Urate-stimulating Excretion Agents Sales (K Units) by Application (2027–2032)
 Table 62. Global Urate-stimulating Excretion Agents Sales Market Share by Application (2021–2026)
 Table 63. Global Urate-stimulating Excretion Agents Sales Market Share by Application (2027–2032)
 Table 64. Global Urate-stimulating Excretion Agents Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Urate-stimulating Excretion Agents Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021–2026)
 Table 67. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2027–2032)
 Table 68. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Application (2027–2032)
 Table 70. Fuji Yakuhin Company Information
 Table 71. Fuji Yakuhin Description and Business Overview
 Table 72. Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Fuji Yakuhin Urate-stimulating Excretion Agents Product
 Table 74. Fuji Yakuhin Recent Developments/Updates
 Table 75. Lannett Company Company Information
 Table 76. Lannett Company Description and Business Overview
 Table 77. Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Lannett Company Urate-stimulating Excretion Agents Product
 Table 79. Lannett Company Recent Developments/Updates
 Table 80. Teva Company Information
 Table 81. Teva Description and Business Overview
 Table 82. Teva Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Teva Urate-stimulating Excretion Agents Product
 Table 84. Teva Recent Developments/Updates
 Table 85. Eisai Company Information
 Table 86. Eisai Description and Business Overview
 Table 87. Eisai Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Eisai Urate-stimulating Excretion Agents Product
 Table 89. Eisai Recent Developments/Updates
 Table 90. AstraZeneca Company Information
 Table 91. AstraZeneca Description and Business Overview
 Table 92. AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. AstraZeneca Urate-stimulating Excretion Agents Product
 Table 94. AstraZeneca Recent Developments/Updates
 Table 95. Towa Pharmaceutical Company Information
 Table 96. Towa Pharmaceutical Description and Business Overview
 Table 97. Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Towa Pharmaceutical Urate-stimulating Excretion Agents Product
 Table 99. Towa Pharmaceutical Recent Developments/Updates
 Table 100. Excella Company Information
 Table 101. Excella Description and Business Overview
 Table 102. Excella Urate-stimulating Excretion Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Excella Urate-stimulating Excretion Agents Product
 Table 104. Excella Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Urate-stimulating Excretion Agents Distributors List
 Table 108. Urate-stimulating Excretion Agents Customers List
 Table 109. Urate-stimulating Excretion Agents Market Trends
 Table 110. Urate-stimulating Excretion Agents Market Drivers
 Table 111. Urate-stimulating Excretion Agents Market Challenges
 Table 112. Urate-stimulating Excretion Agents Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Urate-stimulating Excretion Agents
 Figure 2. Global Urate-stimulating Excretion Agents Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Urate-stimulating Excretion Agents Market Share by Type: 2025 & 2032
 Figure 4. Benzbromarone Product Picture
 Figure 5. Lesinurad Product Picture
 Figure 6. Dotinurad Product Picture
 Figure 7. Probenecid Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Urate-stimulating Excretion Agents Market Value by Application (US$ Million), 2021–2032
 Figure 10. Global Urate-stimulating Excretion Agents Market Share by Application: 2025 & 2032
 Figure 11. Hospitals and Clinics
 Figure 12. Retail Pharmacies
 Figure 13. Other
 Figure 14. Global Urate-stimulating Excretion Agents Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Urate-stimulating Excretion Agents Market Size (US$ Million), 2021–2032
 Figure 16. Global Urate-stimulating Excretion Agents Sales (K Units), 2021–2032
 Figure 17. Global Urate-stimulating Excretion Agents Average Price (US$/Unit), 2021–2032
 Figure 18. Urate-stimulating Excretion Agents Report Years Considered
 Figure 19. Urate-stimulating Excretion Agents Sales Share by Manufacturers in 2025
 Figure 20. Global Urate-stimulating Excretion Agents Revenue Share by Manufacturers in 2025
 Figure 21. Top 5 and Top 10 Global Urate-stimulating Excretion Agents Players: Market Share by Revenue in Urate-stimulating Excretion Agents in 2025
 Figure 22. Urate-stimulating Excretion Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 23. Global Urate-stimulating Excretion Agents Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 24. North America Urate-stimulating Excretion Agents Sales Market Share by Country (2021–2032)
 Figure 25. North America Urate-stimulating Excretion Agents Revenue Market Share by Country (2021–2032)
 Figure 26. United States Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Canada Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Europe Urate-stimulating Excretion Agents Sales Market Share by Country (2021–2032)
 Figure 29. Europe Urate-stimulating Excretion Agents Revenue Market Share by Country (2021–2032)
 Figure 30. Germany Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. France Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. U.K. Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Italy Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Russia Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Asia Pacific Urate-stimulating Excretion Agents Sales Market Share by Region (2021–2032)
 Figure 36. Asia Pacific Urate-stimulating Excretion Agents Revenue Market Share by Region (2021–2032)
 Figure 37. China Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Japan Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. South Korea Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. India Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Australia Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. China Taiwan Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Southeast Asia Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Latin America Urate-stimulating Excretion Agents Sales Market Share by Country (2021–2032)
 Figure 45. Latin America Urate-stimulating Excretion Agents Revenue Market Share by Country (2021–2032)
 Figure 46. Mexico Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Brazil Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Argentina Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Colombia Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Middle East and Africa Urate-stimulating Excretion Agents Sales Market Share by Country (2021–2032)
 Figure 51. Middle East and Africa Urate-stimulating Excretion Agents Revenue Market Share by Country (2021–2032)
 Figure 52. Turkey Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Saudi Arabia Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. UAE Urate-stimulating Excretion Agents Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Global Sales Market Share of Urate-stimulating Excretion Agents by Type (2021–2032)
 Figure 56. Global Revenue Market Share of Urate-stimulating Excretion Agents by Type (2021–2032)
 Figure 57. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Type (2021–2032)
 Figure 58. Global Sales Market Share of Urate-stimulating Excretion Agents by Application (2021–2032)
 Figure 59. Global Revenue Market Share of Urate-stimulating Excretion Agents by Application (2021–2032)
 Figure 60. Global Urate-stimulating Excretion Agents Price (US$/Unit) by Application (2021–2032)
 Figure 61. Urate-stimulating Excretion Agents Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Uric Acid lowering Drugs Market Research Report 2024
Global Drugs for Treating Hyperuricemia Market Research Report 2024
Global Uric Acid Production Inhibitors Market Research Report 2024
Global Dotinurad Tablets Market Research Report 2024
Global Uric Acid Analyzer Market Research Report 2024
Global Probenecid Tablets Market Research Report 2024
Global Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market Research Report 2024
Antihyperuricemic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Uric Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hyperuricemia Micromolecular Drugs Market Research Report 2024
Global Chronic Gout Treatment Drug Market Research Report 2024
Uric Acid Health Supplement Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benzbromarone Tablets Market Research Report 2024
Global Uric Acid Meter Market Research Report 2025
Global Topiroxostat Tablets Market Research Report 2024
Global Febuxostat API Market Research Report 2024
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Drugs of Ursodeoxycholic Acid Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urinary pH Modifiers Market Research Report 2024
Global Drugs for the Treatment of Refractory Gout Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions